Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)

PURPOSE: Tumor Treating Fields (TTFields) therapy, a noninvasive, anti-mitotic treatment modality, is approved for recurrent glioblastoma (rGBM) and newly diagnosed GBM based on phase III, EF-11 (NCT00379470) and EF-14 (NCT00916409) studies, respectively. The EF-19 study aimed to evaluate efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Jay-Jiguang, Goldlust, Samuel A., Kleinberg, Lawrence R., Honnorat, Jérôme, Oberheim Bush, Nancy Ann, Ram, Zvi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568629/
https://www.ncbi.nlm.nih.gov/pubmed/36239858
http://dx.doi.org/10.1007/s12672-022-00555-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568629/
https://www.ncbi.nlm.nih.gov/pubmed/36239858
http://dx.doi.org/10.1007/s12672-022-00555-5

Ejemplares similares